Home›Orforglipron

Orforglipron

Also known as: Foundayo

4 interactions on record

Orforglipron has 4 known drug interactions based on U.S. FDA drug labeling data. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Ritonavir, Simvastatin, Insulin Human. Patients taking Orforglipron should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 4
Major: 2
Moderate: 2

Major (2)

Orforglipron + Ritonavir— Strong CYP3A4 inhibitor that also inhibits OATP1B; avoid concomitant use as it significantly increases FOUNDAYO plasma c…
Orforglipron + Simvastatin— Do not exceed simvastatin 20 mg once daily; concomitant use increases simvastatin acid exposure two-fold, which may be c…

Moderate (2)

Orforglipron + Insulin Human— When initiating FOUNDAYO, consider reducing the dose of concomitantly administered insulin due to potential additive eff…
Orforglipron + Sulfonylurea— When initiating FOUNDAYO, consider reducing the dose of concomitantly administered sulfonylureas due to potential additi…

Orforglipron + Ritonavir⚠️Major

Strong CYP3A4 inhibitor that also inhibits OATP1B; avoid concomitant use as it significantly increases FOUNDAYO plasma concentrations and risk of adverse reactions.

Orforglipron + Simvastatin⚠️Major

Do not exceed simvastatin 20 mg once daily; concomitant use increases simvastatin acid exposure two-fold, which may be clinically meaningful.

Orforglipron + Insulin Human🟡Moderate

When initiating FOUNDAYO, consider reducing the dose of concomitantly administered insulin due to potential additive effects on glucose lowering.

Orforglipron + Sulfonylurea🟡Moderate

When initiating FOUNDAYO, consider reducing the dose of concomitantly administered sulfonylureas due to potential additive effects on glucose lowering.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.